ArticleBJC reports2024
Long term follow-up of women treated for screen detected atypical ductal hyperplasia or lobular neoplasia in a large UK screening centre.
Article in BJC reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Epidemiology, early detection, and management of breast cancer in China: A comprehensive review.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAtypical ductal hyperplasia (ADH) and lobular neoplasia (LN) increase subsequent breast cancer (BC) risk. However, optimal surveillance and risk reduction regimes remain uncertain. We report management and outcomes of women with ADH and LN to provide data on potential screening/prevention strategies.
methodsWomen diagnosed with screen detected ADH and/or LN between 2010-2018 at our institution were identified and demographic data, MDT decisions and BC diagnoses extracted from electronic patient records in 2019 and 2023.
resultsOf 107 women, 74 were discharged to the NHS Breast Screening Programme and 33 were offered enhanced screening (ES). The proportion offered ES increased significantly over time (p = 0.037). 15/105 (14.3%) developed BC (median follow-up 117 months), 9 screen-detected and 6 symptomatic, with 3 interval cancers diagnosed 12-25 months following their last screen. 3/15 were lymph node positive and 13/14 invasive cancers were estrogen receptor (ER) positive. BC incidence rate was 1499.6/100,000 women/year (SIR = 4.7), lower in the first 5 years of follow-up compared with post 5 years.
conclusionsIn women with ADH/LN most BCs occur beyond 5 years. ES regimens should therefore extend to at least 10 years and be at least biennial. Preventative therapy should be considered given the high BC SIR and ER positivity of subsequent tumours.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.